2.19
-0.03(-1.35%)
Currency In USD
| Previous Close | 2.22 |
| Open | 2.19 |
| Day High | 2.25 |
| Day Low | 2.11 |
| 52-Week High | 4.65 |
| 52-Week Low | 1.35 |
| Volume | 1.09M |
| Average Volume | 1.05M |
| Market Cap | 131.29M |
| PE | -1.68 |
| EPS | -1.3 |
| Moving Average 50 Days | 1.86 |
| Moving Average 200 Days | 2.62 |
| Change | -0.03 |
If you invested $1000 in Eledon Pharmaceuticals, Inc. (ELDN) 10 years ago, it would be worth $2.16 as of February 21, 2026 at a share price of $2.19. Whereas If you bought $1000 worth of Eledon Pharmaceuticals, Inc. (ELDN) shares 5 years ago, it would be worth $117.62 as of February 21, 2026 at a share price of $2.19.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Eledon Pharmaceuticals to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026
GlobeNewswire Inc.
Feb 05, 2026 9:10 PM GMT
IRVINE, Calif., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (Nasdaq: ELDN) today announced that Steven Perrin, Ph.D., President and Chief Scientific Officer will participate in a fireside chat at the upcoming Guggenhei
Eledon Pharmaceuticals Presents Long-Term Phase 1b Data for Tegoprubart in Kidney Transplant Patients at the American Society of Transplant Surgeons Winter Symposium
GlobeNewswire Inc.
Jan 23, 2026 12:00 PM GMT
Data from eight participants continue to support safety and tolerability profile of tegoprubart Mean eGFR increased over the measurement period, from 67.0 mL/min/1.73 m² at 12 months to 74.2 mL/min/1.73 m² at 24 months IRVINE, Calif., Jan. 23, 2026
Eledon Pharmaceuticals Highlights Recent Business Milestones and Provides 2026 Outlook
GlobeNewswire Inc.
Jan 08, 2026 9:05 PM GMT
Phase 2 BESTOW trial data evaluating tegoprubart in kidney transplantation showed favorable efficacy, safety and tolerability, supporting advancement into Phase 3 development Reported positive preliminary results from first six patients with type 1 d